Stockscreener 앱 받기
65.69
2.40%
1.54
시간 외 거래:
66.99
1.30
+1.98%
전일 마감가:
$64.15
열려 있는:
$64.3
하루 거래량:
931.11K
Relative Volume:
0.83
시가총액:
$4.55B
수익:
$35.93M
순이익/손실:
$-244.56M
주가수익비율:
-16.63
EPS:
-3.95
순현금흐름:
$-157.31M
1주 성능:
+6.92%
1개월 성능:
+21.36%
6개월 성능:
+59.06%
1년 성능:
+20.09%
1일 변동 폭
$64.27
$66.43
1주일 범위
$61.33
$66.43
52주 변동 폭
$33.19
$66.43
Merus N V Stock (MRUS) Company Profile
명칭
Merus N V
전화
31 030 253 8800
주소
YALELAAN 62, 3584 CM UTRECHT
MRUS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
65.69 | 4.78B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-13 | 개시 | Piper Sandler | Overweight |
| 2025-02-07 | 개시 | Wells Fargo | Overweight |
| 2024-11-21 | 개시 | Goldman | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-03-28 | 개시 | Truist | Buy |
| 2024-03-04 | 재확인 | Needham | Buy |
| 2023-11-02 | 개시 | Canaccord Genuity | Buy |
| 2023-08-21 | 개시 | TD Cowen | Outperform |
| 2022-08-02 | 개시 | Stifel | Buy |
| 2022-02-11 | 개시 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Needham | Buy |
| 2021-11-17 | 재개 | Guggenheim | Buy |
| 2021-06-07 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-04-08 | 개시 | William Blair | Outperform |
| 2021-03-16 | 개시 | SVB Leerink | Outperform |
| 2020-06-26 | 개시 | H.C. Wainwright | Buy |
| 2020-05-27 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | 재개 | Guggenheim | Buy |
| 2019-06-28 | 개시 | ROTH Capital | Buy |
| 2019-04-12 | 재개 | Guggenheim | Buy |
| 2019-04-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | 개시 | Berenberg | Buy |
| 2018-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-03-21 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-12-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2016-11-07 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-06-13 | 개시 | Citigroup | Buy |
| 2016-06-13 | 개시 | Guggenheim | Buy |
| 2016-06-13 | 개시 | Wedbush | Outperform |
모두보기
Merus N V 주식(MRUS)의 최신 뉴스
What analysts say about Merus N.V. stockMarket-leading profit generation - Autocar Professional
Merus N.V. Stock Analysis and ForecastPowerful market insights - jammulinksnews.com
What drives Merus N.V. stock pricePhenomenal trading returns - Autocar Professional
Is Merus N.V. a good long term investmentRapidly expanding wealth - Autocar Professional
Merus Shares Soar 3.24% On Positive Cancer Study Update - AInvest
Merus NV stock hits all-time high, reaching 62.98 USD - Investing.com
Merus Shares Surge Amid Promising Cancer Study - TipRanks
Merus N.V. Advances in Head and Neck Cancer Treatment with Phase 3 Study - TipRanks
Learn to Evaluate (MRUS) using the Charts - news.stocktradersdaily.com
Merus N.V. (NASDAQ:MRUS) Shares Sold by Teacher Retirement System of Texas - Defense World
Merus N.V. (NASDAQ:MRUS) Given Average Rating of “Buy” by Analysts - Defense World
Why Merus N.V. stock attracts strong analyst attentionFree Access to Community - Newser
How Merus N.V. stock performs during market volatilitySwing Trade Signals - newser.com
Merus (MRUS) Gets a Buy from H.C. Wainwright - The Globe and Mail
What makes Merus N.V. stock price move sharplyAlpha Stock Ideas - Newser
Insider Selling: Merus N.V. (NASDAQ:MRUS) COO Sells $924,275.00 in Stock - Defense World
Merus (NASDAQ:MRUS) Upgraded by Wall Street Zen to Hold Rating - Defense World
MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success - sharewise.com
Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III - Insider Monkey
Merus N.V. (MRUS): A Breakthrough in Oncology with Petosemtamab's ASCO-Backed Potential - AInvest
Merus N.V.’s Promising Phase 3 Study in Head and Neck Cancer: What Investors Need to Know - TipRanks
Merus gains after mid-stage trial data for lead asset in head and neck cancer - MSN
(MRUS) Technical Data - news.stocktradersdaily.com
Merus N.V.’s SWOT analysis: promising antibody platform drives stock potential - Investing.com India
Merus N.V.’s SWOT analysis: promising antibody platform drives stock potential By Investing.com - Investing.com South Africa
Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus (NASDAQ:BCAX) - Seeking Alpha
The Netherlands: Merus raises US$300m from underwritten public offering - Investors in Healthcare
Why Merus N.V. (MRUS) Crashed On Wednesday - MSN
Merus N.V. announces proposed public offering of common shares - MSN
Merus dips 7%, prices $300M stock at $57 per share - MSN
Merus Announces Public Offering of Common Shares - TipRanks
Merus Raises $300m After ASCO Success - insights.citeline.com
Sector Update: Health Care Stocks Mixed Premarket Wednesday - marketscreener.com
Merus N V (MRUS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Merus N V 주식 (MRUS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Silverman Peter B. | COO & GC |
Jul 17 '25 |
Sale |
60.00 |
25,000 |
1,500,000 |
0 |
3.32%
1.57%
자본화:
|
볼륨(24시간):